Eli Lilly (LLY) said the Australian Therapeutic Goods Administration granted marketing authorization for Kisunla, an injection for intravenous infusion given every four weeks to treat mild cognitive impairment and mild dementia due to Alzheimer's disease.

An estimated 600,000 Australians are living with Alzheimer's, and 450,000 in the early stages could be evaluated to determine eligibility for treatment with Kisunla, or donanemab. the company said Wednesday in a statement.